Mutations in the ligand-binding domain of the thyroid hormone receptor β (TRβ) lead to resistance to thyroid hormone (RTH). These TRβ mutants function in a dominant-negative fashion to interfere with the transcription activity of wild-type thyroid hormone receptors (TRs), leading to dysregulation of the pituitary-thyroid axis and resistance in peripheral tissues. The molecular mechanism by which TRβ mutants cause RTH has been postulated to be an inability of the mutants to properly release the nuclear corepressors (NCORs), thereby inhibiting thyroid hormone (TH)-mediated transcription activity. To test this hypothesis in vivo, we crossed Thrb PV mice (a model of RTH) expressing a human TRβ mutant (PV) with mice expressing a mutant Ncor1 allele (Ncor1 ΔID mice) that cannot recruit a TR or a PV mutant. Remarkably, in the presence of NCOR1ΔID, the abnormally elevated thyroid-stimulating hormone and TH levels found in Thrb PV mice were modestly but significantly corrected. Furthermore, thyroid hyperplasia, weight loss, and other hallmarks of RTH were also partially reverted in mice expressing NCOR1ΔID. Taken together, these data suggest that the aberrant recruitment of NCOR1 by RTH TRβ mutants leads to clinical RTH in humans. The present study suggests that therapies aimed at the TR-NCOR1 interaction or its downstream actions could be tested as potential targets in treating RTH.
Mutations in the ligand-binding domain of the thyroid hormone receptor β (TRβ) lead to resistance to thyroid hormone (RTH). These TRβ mutants function in a dominant-negative fashion to interfere with the transcription activity of wild-type thyroid hormone receptors (TRs), leading to dysregulation of the pituitary-thyroid axis and resistance in peripheral tissues. The molecular mechanism by which TRβ mutants cause RTH has been postulated to be an inability of the mutants to properly release the nuclear corepressors (NCORs), thereby inhibiting thyroid hormone (TH)-mediated transcription activity. To test this hypothesis in vivo, we crossed Thrb PV mice (a model of RTH) expressing a human TRβ mutant (PV) with mice expressing a mutant Ncor1 allele (Ncor1 ΔID mice) that cannot recruit a TR or a PV mutant. Remarkably, in the presence of NCOR1ΔID, the abnormally elevated thyroid-stimulating hormone and TH levels found in Thrb PV mice were modestly but significantly corrected. Furthermore, thyroid hyperplasia, weight loss, and other hallmarks of RTH were also partially reverted in mice expressing NCOR1ΔID. Taken together, these data suggest that the aberrant recruitment of NCOR1 by RTH TRβ mutants leads to clinical RTH in humans. The present study suggests that therapies aimed at the TR-NCOR1 interaction or its downstream actions could be tested as potential targets in treating RTH.
thyroid hormone receptor mutant | mouse models | dominant negative activity T hyroid hormone (TH) signaling plays a crucial role in developing and maintaining metabolic homeostasis in humans. The genomic actions of TH are mediated by the thyroid hormone receptor (TR) isoforms α1, β1, and β2, which regulate target genes in the presence or absence of TH via recruitment of coregulatory complexes (1, 2) . In the absence of T3 on target genes that are positively regulated by T3, TRs recruit the nuclear corepressors NCOR1 and NCOR2 for transcriptional repression. The addition of T3 leads to a conformational change in the TR that releases the NCOR1/NCOR2 complex and allows for the recruitment of a multiprotein coactivator complex for transcriptional activation (3) . Recent advances made by our group and others have expanded this model and shown that NCOR1 and NCOR2 play a role in determining T3 sensitivity in vivo, suggesting that corepressors can be recruited to TR in the presence of T3 (4) (5) (6) .
Resistance to thyroid hormone (RTH) is an autosomal dominant human disease due to mutations in the thyroid hormone receptor β (TRβ) ligand-binding domain that prevent T3 binding and alter coregulator recruitment. RTH manifests itself by an inappropriately elevated thyroid-stimulating hormone (TSH) in the face of increased TH levels and with a complex clinical phenotype (7) . Knock-in mouse models that faithfully recreate the human disease and provide an opportunity to explore novel therapeutic approaches to the disorder have been developed (8, 9) .
Although RTH TRβ mutations are predicted to impair T3-mediated activation or repression of target genes, the exact mechanism of action of these dominant negative mutants has not been elucidated in vivo. Earlier work has established that TRβ mutants can compete directly with the wild-type TR for DNA binding and also compete for limiting coregulators, thus impairing transcriptional activation by wild-type TRs (10, 11) . However, subsequent cell culture experiments have demonstrated that constitutive recruitment of NCOR1/NCOR2 was critical to the dominant negative phenotype of TRβ mutants (12, 13) . A similar hypothesis has been put forward for the peroxisome proliferator-activated receptor γ ligand-binding domain mutants that cause lipodystrophy (14) . If this were the case, then abrogation of the TRβ mutant-NCOR1/NCOR2 interaction should ameliorate the syndrome of RTH, and this outcome would suggest a therapeutic strategy for the disorder.
To test this hypothesis, we took advantage of a mouse model of human RTH, the Thrb PV mouse that harbors a knock-in mutation (denoted PV) of the Thrb gene (8) . The PV mutation, identified in a patient with RTH, has a frame-shift mutation in the C-terminal 14 amino acids, resulting in the complete loss of T3-binding activity and transcription capacity (15) . Thrb PV mice reproduce human RTH with elevated TH levels accompanied by nonsuppressible serum TSH levels and other abnormalities similar to human RTH (7). We crossed Thrb PV mice with mice that globally express an NCOR1 mutant protein (NCOR1ΔID) in which the receptor interaction domains have been modified so that it cannot interact with the TR (5). We have previously shown that Ncor1 ΔID mice have increased sensitivity to TH and a normal TSH despite low T4 and T3 levels, demonstrating the specificity of NCOR1 for regulating the thyroid axis in vivo (6) . Remarkably, expression of NCOR1ΔID protein in heterozygous and homozygous Thrb PV mice significantly normalized the dysregulation of the pituitary-thyroid axis and other abnormalities in peripheral target tissues. Thus, strategies directed against NCOR1 recruitment or the complex that it recruits could potentially serve as therapeutic targets for this disorder.
Results
PV Does Not Interact with NCOR1ΔID. We have shown previously that NCOR1ΔID lacking the N3 and N2 receptor-interacting domains prevents recruitment of TR in vivo (5) . To confirm that NCOR1ΔID is also unable to recruit PV, we performed coimmunoprecipitation studies both in transfected 293T cells and in vivo in wild-type (WT), Thrb PV/PV Ncor1 +/+ , and Thrb PV/PV Ncor1 ΔID/ΔID mice. In 293T cells expressing PV via viral transduction and transfected with expression plasmid of NCOR1, specific antiserum directed against PV (#302) interacted with NCOR1 (lane 3, Fig. 1A ). In contrast, when PV-expressing cells were transfected with NCOR1ΔID, PV interacted only with the endogenous NCOR1 (lane 6, Fig. 1A) , not with the faster-migrating NCOR1ΔID (lower band, lane 8, Fig. 1A ). To confirm that this was the case in vivo, we carried out similar coimmu-noprecipitation analysis from liver nuclear extracts (Fig. 1B) . In the liver of WT mice, when anti-TR antibody (C4) was used in the immunoprecipitation followed by anti-NCOR1 antibodies, NCOR1 was clearly visible (lane 2, Fig. 1B 
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ΔID/ΔID mice. Thus, the cross of Ncor1
ΔID and Thrb PV mice will allow us to determine if NCOR1 plays a role in the pathogenesis of RTH in vivo.
Deletion of Receptor Interaction Domains in NCOR1 Ameliorates RTH in the Pituitary-Thyroid Axis in Vivo. The hallmark of RTH is increased circulating levels of serum T3 and T4 accompanied by normal or elevated serum TSH levels (7) . Indeed, the TRβPV mutation in both mice and humans results in an elevated serum TSH in the presence of increased thyroid hormone levels (8) . This phenotype is thought to be secondary to the ability of the mutant TRβ isoform to prevent negative regulation of TSH subunit genes in the pituitary by T3. To determine if the aberrant recruitment of NCOR1 by PV is responsible, we crossed Thrb PV mice with Ncor1 ΔID mice and then assessed thyroid function in the resulting genotypes. Fig. 2A shows that, compared with WT mice (2.77 ± 0.21 μg/dL, n = 21), serum total T4 (TT4) decreased by 43% in Thrb
ΔID/ΔID mice (1.58 ± 0.09 μg/dL, n = 11), a finding consistent with what we have shown previously and indicative of the importance of NCOR1 in establishing the set point of the thyroid axis (6) . Remarkably, the elevated TT4 levels in Thrb PV/+ Ncor1 +/+ mice (10.20 ± 0.51 μg/dL, n = 32) markedly decreased in Thrb PV/+ Ncor1 ΔID/ΔID mice (5.64 ± 0. 45 μg/dL, n = 17), representing a 45% reduction. Moreover, compared with the elevated TT4 of Thrb PV/PV Ncor1 +/+ mice (32.40 ± 0.66 μg/dL, n = 12), a significant 14% reduction in TT4 was observed in Thrb PV/PV Ncor1 ΔID/ΔID mice (27.91 ± 1.55 μg/dL, n = 12). Therefore, the presence of two mutated alleles of the Ncor1 gene reduced the elevated serum TT4 in both heterozygous and homozygous Thrb PV mice. Serum TT3 levels were also analyzed from mice of all genotypes ( 
+/+ mice (12.31 ± 1.59 ng/dL, n = 9), a more dramatic 55% reduction was observed in Thrb
ΔID/ΔID mice (5.48 ± 0.52 ng/dL, n = 12). Therefore, both the elevated TT4 and TT3 due to the dominant negative action of PV were markedly abrogated by the expression of NCOR1ΔID.
Serum TSH levels were also analyzed, as shown in Fig. 2C . No apparent effect was observed in serum TSH levels by the expression of NCOR1ΔID in WT mice (compare data groups 1 and 2) despite the presence of low TH levels. However, the elevated TSH in Thrb PV/+ Ncor1 +/+ mice decreased by 35% in Thrb PV/+ Ncor1 ΔID/ΔID mice (compare data groups 3-4) and was similar to that found in WT mice. The highly elevated TSH in Thrb PV/PV Ncor1 +/+ mice was also lowered by the expression of NCOR1ΔID in Thrb PV/PV
ΔID/ΔID mice (30% decrease; compare data groups 5 and 6, Fig. 2C ). Taken together, these thyroid function tests show that the expression of NCOR1ΔID ameliorates the syndrome of RTH on the pituitary-thyroid axis. We next examined the effect of the expression of NCOR1ΔID on thyroid growth. No effect of the expression of NCOR1ΔID in Thrb +/+ mice on thyroid growth was observed (compare bar 1 to bar 2, Fig. 3A ), consistent with previous data (6) . Similar to our earlier work (8) Fig. 3B , Left and Right, respectively. The thyroid of the Thrb PV/PV Ncor1 +/+ mice was large with the appearance of hypervascularity, whereas that of the Thrb PV/PV Ncor1 ΔID/ΔID mice was smaller with a more normal appearance. Consistently, histological analysis showed that the extensive hyperplasia exhibited in the thyroid of Thrb PV/PV mice (Fig. 3Cc) reverted to early hyperplasia (Fig. 3Cc) , indicating that proliferation of thyrocytes was inhibited by the expression of NCOR1ΔID in Thrb PV/PV Ncor1 ΔID/ΔID mice. In contrast to the thyroid, comparison of the size of pituitaries among mice with different genotypes did not reveal any effects of NCOR1ΔID.
Effect of the Expression of NCOR1ΔID on the RTH Is Target TissueDependent. Because RTH affects many peripheral target tissues, we also evaluated how the resistance of target tissues was affected by the expression of NCOR1ΔID.
Retarded growth in Thrb PV mice. Consistent with RTH patients, Thrb PV mice exhibit growth retardation by displaying impaired weight gain (8) . We therefore assessed how the expression of NCOR1ΔID affects body weight in Thrb PV mice. Fig. 4A shows that, at the age of 4-6 mo, no effect of NCOR1ΔID was apparent in Thrb +/+ mice (30.19 ± 2.31 g, n = 8 and 29.59 ± 0.95 g, n = 31: compare group 2 and group 1, respectively, in Fig. 4A ), although when younger than 12 wk of age NCoR ΔID mice were slightly lighter than WT mice as previously described (6) . Similarly, the presence of NCORΔID had no effect on the body weight of Thrb PV/+ mice (group 4 vs. group 3). However, consistent with previous findings, Thrb PV/PV Ncor1 +/+ mice displayed impaired growth with a significant 12% reduction in body weight (26.09 ± 0.70 g, n = 39: group 5) compared with that of WT mice (group 1). However, this impairment of growth was ameliorated in Thrb PV/PV Ncor1 ΔID/ΔID mice (31.33 ± 2.32 g, n = 9: group 6) such that the body weight of Thrb PV/PV Ncor1 ΔID/ΔID mice was similar to that of WT mice (group 1, Fig. 4A ). Thus, the impaired weight of Thrb PV/PV Ncor1 +/+ mice is normalized when the NCOR1-PV interaction is disrupted.
Although reduced body weight in Thrb PV mice may be secondary to energy expenditure and body composition, it may also be reflected in delayed bone development (8, 16) mice. These results indicate that, although the expression of NCOR1ΔID impaired the development of long bones, this effect was lost in mice harboring a TRβ mutant; furthermore, NCOR1ΔID had no effect on the action of PV in femurs. Thus, the effect of NCORΔID in preventing loss of body weight is not related to its independent effects on bone development.
Abnormalities in the liver of Thrb PV mice. Previously, we found that the livers of Thrb PV mice are enlarged (17) . We therefore compared the liver weight among mice with different genotypes (Fig. 5A) 
+/+ mice). These results indicate that NCOR1ΔID acted synergistically with PV to increase liver weight.
In addition to enhanced liver growth, Thrb PV/PV mice exhibit abnormalities in the regulation of serum cholesterol (18) . As shown in 
ΔID/ΔID mice (group 6 vs. group 5). Thus, the expression of NCOR1ΔID does not improve the metabolism of serum cholesterol in RTH. 
Effect of NCOR1ΔID on PV-Mediated Gene Expression Patterns Is
Target Gene-Dependent. Our observation that the loss of the PV-NCOR1 interaction led to a decrease in the serum TSH levels of Thrb PV mice (Fig. 2C ) prompted us to examine whether the reduction of serum TSH is mediated at the level of transcription. We analyzed the expression of the TSHβ subunit gene (Tshb) and α-glycoprotein common subunit (Cga) genes in the pituitary gland. As shown in Fig. 6Aa, 
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ΔID/ΔID mice (bar 6). Thus, the elevation of Tshb mRNA by PV is prevented when the PV-NCOR1 interaction is blocked. We also examined whether the expression of the Cga gene was affected by NCOR1ΔID (Fig.  6Ab) . In Ncor1 ΔID mice, the expression of the Cga gene moderately decreased (20%) compared with WT mice (bar 2 vs. bar 1: Fig.  6Ab ), but the elevated Cga mRNA due to the dominant negative effect of PV in Thrb PV/PV Ncor1 +/+ mice (bar 5) was not affected in Thrb
PVPV
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ΔID/ΔID mice (compare bar 6 to bar 5: Fig. 6A, b) . Thus, these data suggest that the activation of the Cga expression by PV does not require NCOR1.
In addition to the above negatively regulated genes, we also examined T3-postively regulated genes in the liver of Thrb PV mice (Fig. 6B) 
ΔID/ΔID mice and reverted to a level that was threefold higher than that in WT mice (compare bar 6 to bar 1). We next examined the expression of cholesterol 7a hydroxylase 1 (Cyp7a1), the ratelimiting enzyme that mediates the conversion of cholesterol into bile acids and a known T3 target gene; its dysregulation has been shown to potentially mediate the hypercholesterolemia seen in RTH (Fig. 6Bb) . Similar to Me1, the expression of the Cyp7a1 mRNA was increased 2.8-fold in Thrb 
ΔID/ΔID mice, the PV-mediated repression was also blocked (bar 6). However, the degree of reversal of the PV-mediated repression was smaller than that in Thrb
mice (compare bar 6 to bar 4).
We further evaluated the effect of NCOR1ΔID on the expression of the CCAAT/enhancer-binding protein α (C/ebpα) gene, a known T3-target gene in the liver. Fig. 6Bc , shows that the expression of the C/ebpα gene was repressed by ∼50% in Thrb +/+ mice by the expression of NCOR1ΔID (bar 2 vs. bar 1). Compared with WT mice, a small but significant decrease (∼15%) in the expression of the C/ebpα gene was detected in Thrb PV/+ Ncor1 +/+ mice and in Thrb PV/PV Ncor1 +/+ mice (compare bars 3 and 5 to bar 1), which was further repressed by NCOR1ΔID (bars 4 and 6). Thus, in contrast to the expression patterns of the Me1 and Cyp7a1 genes, the PV-mediated repression of the C/ebpα gene was intensified by NCOR1ΔID (bar 6 vs. bar 5). Thus, the effect of NCOR1ΔID on the PV-mediated abnormal expression of positively regulated genes in the liver is target gene dependent.
Discussion
Although it is an uncommon clinical entity, RTH has long been a model by which to understand thyroid hormone action both clinically and at the molecular level. In addition, RTH has been a model used to understand how mutations in other nuclear receptors mediate disease. The nature of the mutations found in RTH and their effect on the structure of the TRβ isoform have suggested that the disease could be mediated by a defect in the release or recruitment of coregulatory proteins to TRβ rather than simply by the inability of the TRβ to bind ligand. This idea is supported by the fact that deletion of one TRβ allele causes no disease whereas the expression of a single-mutant TRβ allele leads to RTH because of its dominant negative properties (7, 19) . Thus, understanding the molecular pathogenesis of RTH could have significant ramifications for both its treatment and the treatment of other nuclear receptor resistance syndromes in humans.
To address the molecular pathogenesis of RTH in vivo, we introduced a mutant Ncor1 allele (Ncor1 ΔID ) into a mouse model of RTH (the Thrb PV mouse) that faithfully recapitulates this human disease (8) , with evidence of both central and peripheral resistance to TH in the presence of one mutant allele and severe resistance in the homozygous state. Importantly, the fact that NCOR1ΔID cannot interact with either the TRβ (5, 6) or PV in vivo (Fig. 1B) has allowed us to test directly whether NCOR1 mediates the detrimental effects of PV. Remarkably, the elevations in TSH, TT4, and TT3 found in either Thrb PV/+ or Thrb PV/PV mice are modestly but significantly reversed in the presence of two Ncor1 ΔID alleles. The fact that the effects are greater in Thrb PV/+ mice than in Thrb PV/PV mice suggests that the homozygous state might allow for the recruitment of additional corepressors such as NCOR2. This result also establishes the role of a mutated TRβ, PV, and NCOR1 in mediating the central resistance seen in RTH as the introduction of NCOR1ΔID also prevents the elevation in Tshb gene expression seen in either Thrb PV/+ mice or Thrb PV/PV mice (Fig. 6Aa) . Given that the defects in the central regulation of the thyroid axis are necessary for the development and diagnosis of RTH, their partial correction in the presence of NCOR1ΔID suggests that therapies targeting the TR-NCOR1 complex could be therapeutic in RTH.
Although the introduction of NCORΔID into Thrb PV/PV mice lowered serum TSH by 35%, it appeared to have a far more dramatic effect on the thyroid size, pathological hyperplasia, and vascularity seen in the thyroids from Thrb PV/PV mice. Indeed, this effect is consistent with the proliferative effect of PV and its potential role in the development of thyroid carcinoma being dependent upon NCOR1 recruitment in the follicular cell (20, 21) . This cell-autonomous role of NCOR1 in the follicular cell is supported by the decreased ability of Thrb +/+ Ncor1 ΔID/ΔID mice to release T4 and T3 in response to TSH, suggesting that NCOR1 controls thyroid hormone action within the follicular cell. Further studies will be required to demonstrate the effect of the PV-NCOR1 interaction on thyroid growth.
In addition to correcting central resistance to RTH in Thrb PV/+ mice or Thrb PV/PV mice, the introduction of Ncor1ΔID to Thrb PV mice also improved peripheral markers of hormone resistance. The lower body weight seen in Thrb PV/PV mice, potentially a marker of increased energy expenditure in RTH, is increased in the presence of the mutated allele Ncor1ΔID (22) . This result could be partly due to an increase in liver weight. This possibility is supported by regression analysis that shows a highly significant correlation (R 2 = 0.807, P < 0.001) between liver weight and body weight across the two genotypes (Thrb mice expressing NCOR1ΔID, expression of TH target genes (Me1 and Cyp7a1) in the liver is enhanced, an outcome consistent with inhibition of the dominant effect of the TRβ mutant (23) . However, this effect is not present in all genes, as indicated by the findings that the repression of the C/ebpα gene is not reversed in mice expressing NCOR1ΔID, again indicating that the mutant TR can potentially recruit other corepressors. Furthermore, the elevated cholesterol levels found in Thrb PV/PV mice, which are secondary to repression of the Cyp7a1 gene, are not reversed in Thrb PV/PV mice expressing NCOR1ΔID despite enhanced expression of the Cyp7a1 gene. The sustained elevated cholesterol level is likely due to the primary effect of NCOR1ΔID on enhancing cholesterol synthesis that we have shown previously and may also explain the increase in liver weight seen in mice that express NCOR1ΔID (5) .
Surprisingly, despite the correction of TH levels in Thrb PV/+
and Thrb PV/PV mice expressing NCOR1ΔID, the hyperthyroid bone phenotype present in Thrb PV/+ and Thrb PV/PV mice was not corrected. Indeed, it is well established that the bone phenotype present in Thrb PV/+ and Thrb PV/PV mice is the result of juvenile hyperthyroidism with increased ossification and postnatal shortening of bone length due to the excessive actions of the high circulating levels of TH working through the wild-type TRα1 present in bone (8, 24) . Thus, falling TH levels in Thrb PV/+ and Thrb PV/PV mice expressing NCOR1ΔID would be expected to correct this defect, similar to what was seen with body weight. However, it also clear that Ncor1 ΔID mice independently have increased sensitivity to TH and in fact also have a shortened femur length that approaches that found in Thrb PV mice. Thus, it is likely that this premature fusion of the growth plate in Comparison of the expression of malic enzyme (Me1), cholesterol 7α hydroxylase1 (Cyp7a1), and CCAAT/enhancerbinding protein α (C/ebpα) mRNA in the liver of Thrb PV mice. Relative quantification of each target mRNA was determined by arbitrarily setting the control value of WT mice as 1. The level of expression was normalized by signals obtained using specific primers for mouse Gadph. The data are expressed as mean values ± SEM (n = 6-9) with P values shown.
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ΔID mice occurring in the setting of low TH levels could prevent the reversal mediated by the expressed NCOR1ΔID in Thrb PV/+ and Thrb PV/PV mice. In summary, in this study we have established that a mutant TRβ that causes RTH mediates many of its effects by the aberrant recruitment of NCOR1. By preventing the recruitment of NCOR1 in vivo, the RTH phenotype is alleviated centrally and in some peripheral tissues. However, because NCOR1 also mediates sensitivity to TH in the context of TRα1 signaling in bone, the hyperthyroid phenotype in that tissue cannot be reversed. Nonetheless, in view of the lack of effective treatment for RTH so far, the present results suggest that novel therapeutic strategies that target the TR-NCOR1 interaction may benefit patients with RTH.
Materials and Methods
Mouse Strains. This animal study was carried out according to the protocol approved by the National Cancer Institute Animal Care and Use Committee. Mice harboring the Thrb PV gene (Thrb PV mice) were prepared and genotyped as described earlier (8) . Ncor1 ΔID mice were prepared as described by Hormone Assays. The serum levels of total T4 and total T3 were determined using a Gamma Coat T4 and T3 assay RIA kit (DiaSorin). Serum TSH levels were measured as previously described (25) . A cholesterol E kit (Stanbio Laboratory) was used for quantitative determination of total cholesterol in mouse serum.
RNA Isolation and Quantitative Real-Time RT-PCR. Total RNA was extracted from pituitary and liver of mice using TRIzol (Invitrogen). Quantitative realtime RT-PCR was performed with a Quantitect SYBR Green RT-PCR kit (QIAGEN), according to the manufacturer's instructions and using a LightCycler thermal cycler (Roche Diagnostics). Total RNA (200 ng) was used in RT-PCR determinations as described previously (26) . The specific primer sequences are available upon request.
Coimmunoprecipitation. 293T cells were plated at a density of 1 × 10 6 in a 10-cm dish and transfected with 4 μg of expression plasmid for Ncor1 or Ncor1ΔID using Lipofectamine 2000. At the same time, cells were infected with adenoviruses encoding Flag-tagged PV at a multiplicity of infection (MOI) of 10. After lysing the cells, immunoprecipitation (1 mg of total lysates) was carried out using monoclonal anti-PV antibody (#302; 4 μg) or IgG as negative control followed by Western blot analysis using polyclonal affinity-purified anti-NCOR1 antibodies [PHQQ; generated against a C-terminal NCoR peptide (PHQQNRIWEREPAPLLSAQ); 2 μg/mL].
In vivo coimmunoprecipitaton was carried out using nuclear extracts prepared from livers of Thrb PV/PV Ncor1 +/+ mice and Thrb PV/PV Ncor1 ΔID/ΔID mice, as described previously (27) . Nuclear extracts (1.1 mg protein) were incubated overnight with 5 μg of a mouse monoclonal anti-TR (C4), anti PV (#302), or anti-MOPC (Sigma Inc, MOPC141). MOPC contains IgG2b, k derived from ascites originated from mineral oil-induced plasmacytoma. Bound proteins were analyzed by SDS/PAGE followed by Western blot analysis using PHQQ.
Histological Analysis. The thyroid gland was dissected and embedded in paraffin. Five-micrometer-thick sections were prepared and stained with hematoxylin and eosin. For each animal, single random sections through the thyroid were examined.
Statistical Analysis. All data are expressed as mean ± the SEM. Differences between groups were examined for statistical significance using Student's t test with the use of GraphPad Prism 4.0a (GraphPad Software). P < 0.05 is considered statistically significant.
